Loading...
•
Sep 30, 2021
Twist Bioscience Q4 2021 Earnings Report
Reported record revenue for both the quarter and the fiscal year and a gross margin of more than 40% for the quarter and 39% for the year.
Key Takeaways
Twist Bioscience reported financial results for the fourth quarter and full year fiscal 2021, achieving record revenues in fiscal 2021 of $132.3M, a 47% increase over fiscal 2020.
Delivered significant revenue growth by diversifying and expanding customer base in synbio and NGS.
Had 34 partners, 41 active and 32 completed programs in biopharma as of the end of September 2021.
Expects to have the first Twist-discovered antibody in the clinic in 2022, subject to regulatory approval.
Signed an agreement to acquire Abveris to augment capabilities by adding animal-based discovery.
Forward Guidance
Twist expects revenue of $183M to $193M for fiscal 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...